Free Trial

Nathan Treybeck Analyst Performance

Equity Research Vice President at Wells Fargo & Company

Nathan Treybeck is a stock analyst at Wells Fargo & Company in the medical sector, covering 4 publicly traded companies. Over the past year, Nathan Treybeck has issued 4 stock ratings, including buy and hold recommendations. While full access to Nathan Treybeck's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Nathan Treybeck's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Nathan Treybeck at Wells Fargo & Company, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
3 companies
NYSE
25.0% of companies on NYSE
1 company

Nathan Treybeck, an analyst at Wells Fargo & Company, currently covers 4 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Nathan Treybeck of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
2 companies
50.0%
MEDICAL INFO SYS
1 company
25.0%
MED PRODUCTS
1 company
25.0%

Nathan Treybeck's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
8/7/2025Lower Price Target$40.20$58.00Overweight
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
8/1/2025Boost Price Target$164.95$180.00Overweight
Integer Holdings Corporation stock logo
ITGR
Integer
7/25/2025Lower Price Target$106.24$132.00Overweight
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2/13/2025Initiated Coverage$96.32$95.00Equal Weight